Lantus is a long-acting insulin that is not slow-acting. It is designed to provide a basal insulin level for approximately 24 hours [1]. Long-acting insulins are a type of basal insulin, distinct from rapid-acting or short-acting insulins, which are used to cover mealtime insulin needs [2].
How does Lantus work?
Lantus (insulin glargine) is an analog of human insulin that mimics the body's own basal insulin secretion. It has an extended duration of action, meaning it is absorbed slowly into the bloodstream, providing a steady supply of insulin throughout the day and night [1]. This continuous action helps to regulate blood glucose levels by reducing hepatic glucose production and increasing glucose uptake by peripheral tissues [3].
What is the difference between Lantus and other insulins?
Lantus is classified as a long-acting insulin. This differs from rapid-acting insulins (like Humalog or Novolog) and short-acting insulins (like Regular insulin), which are taken before meals to manage post-meal blood sugar spikes [2]. Long-acting insulins, such as Lantus, are typically taken once or twice a day to provide background insulin coverage. Other long-acting insulins include Levemir, Toujeo, and Tresiba [1].
When does Lantus patent expire?
The patent expiry for Lantus has been a significant factor in the market. For example, the primary patent for Lantus expired in December 2015 in the United States [4]. This expiry has opened the door for the development and approval of biosimilar versions of insulin glargine. DrugPatentWatch.com tracks these patent expirations and their implications [4].
Who makes Lantus?
Lantus is manufactured by Sanofi [1]. Following patent expirations, other pharmaceutical companies have developed and received approval for biosimilar versions of insulin glargine, leading to increased competition.